These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33508648)

  • 1. Oxidative stress activity of fingolimod in multiple sclerosis.
    Yevgi R; Demir R
    Clin Neurol Neurosurg; 2021 Mar; 202():106500. PubMed ID: 33508648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
    BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    Abdel-Dayem MA; Shaker ME; Gameil NM
    J Neuroimmunol; 2019 Dec; 337():577062. PubMed ID: 31521828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG
    Deiva K; Huppke P; Banwell B; Chitnis T; Gärtner J; Krupp L; Waubant E; Stites T; Pearce GL; Merschhemke M
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):58-66. PubMed ID: 31467033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
    J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
    Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
    Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis, a treatable disease .
    Doshi A; Chataway J
    Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
    D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
    Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future trends in multiple sclerosis management: Near East perspective.
    Hatem A; El Ayoubi NK; Habahbeh M; Ghanim Z; Al-Naqshbandi M; Raki A; Joudi H; Sahraian MA
    Mult Scler Relat Disord; 2023 Aug; 76():104800. PubMed ID: 37307691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report.
    Maciejek Z; Wójcik-Drączkowska H; Wawrzyniak S; Niezgodzińska-Maciejek A
    Neurol Neurochir Pol; 2013; 47(2):145-51. PubMed ID: 23650003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.
    Adamczyk B; Wawrzyniak S; Kasperczyk S; Adamczyk-Sowa M
    Oxid Med Cell Longev; 2017; 2017():9625806. PubMed ID: 29138683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.